Somatic hypermutation is a specific mutagenic process that can diversify the Ig genes at several stages of the B cell differentiation pathway: either outside an immune response, leading to repertoire diversification, or during antigen driven responses, leading to affinity maturation through the selection of B cells displaying better antigen-binding capacities ([@bib1]).

Hypermutation is initiated by activation-induced cytidine deaminase (AID) through an enzymatic process that deaminates cytidines into uracils and is essentially, but not exclusively, targeted at the heavy and light chain V genes of the Ig locus (reference [@bib2]; for review see references [@bib3], [@bib4]). However, mutations at the Ig locus are equally distributed at G/C and A/T bases, which requires that specific error-prone repair pathways process this C-focused lesion to broaden its mutation spectrum ([@bib5]). In spite of the large number of repair factors able to handle uracils within the eukaryotic cell, only two of them have been shown to contribute to hypermutation: uracil *N*-glycosylase (UNG) and the DNA-binding moiety of the mismatch repair complex (MSH2--MSH6) ([@bib6]--[@bib14]). When these two factors are missing, the mutation pattern becomes the imprint of the sole AID action, the replication of uracils generated on both DNA strands resulting in C to T and G to A transitions at the sites of AID deamination ([@bib14]).

Error-prone DNA polymerases, in particular those involved in the replicative bypass of DNA lesions, have been considered as prime candidates to generate mutations at A/T base pairs from the initial deamination event. The Ig gene mutation pattern of patients affected with the variant form of the xeroderma pigmentosum syndrome, a genetic disease corresponding to inactivation of DNA polymerase η (pol η) ([@bib15]), was shown to be markedly, albeit variably, reduced in A/T mutagenesis ([@bib16]--[@bib18]). Inactivation of pol η in the mouse confirmed this phenotype and resulted in a more homogeneous reduction in A/T mutations ([@bib19]--[@bib21]). Similarly, inactivation of the MSH2 protein (or of its MSH6 and exonuclease-1 partners) in the mouse has been shown to result in a decreased mutation load at A/T bases ([@bib7]--[@bib13]). These observations have led to a model of hypermutation in which UNG-mediated repair would be responsible for most mutations at G/C bases, whereas the MSH2 pathway would generate the major part of A/T mutations ([@bib14]).

But how is the residual A/T mutagenesis observed in both pol η or MSH2-deficient animals generated? We previously reported that, in *Polh^−/−^* mice, the A/T mutation pattern bears the signature of a different enzyme ([@bib19]), most probably pol κ, which has an unusual bias toward transversions ([@bib22], [@bib23]). The absence of effect of pol κ deficiency on the Ig mutation pattern ([@bib24]--[@bib26]) strongly suggested that this enzyme is probably not a normal actor in hypermutation but would rather be recruited only in the absence of the regular polymerase partner. We show in this report that the residual A/T mutagenesis observed in MSH2-deficient mice is contributed by pol η, now driven by the UNG pathway, thus establishing pol η as the sole polymerase generating A/T mutations during the physiological mutation process. The recruitment of pol η by UNG is discussed in the context of the striking modification of the mutation pattern observed in MSH2-deficient animals, which leads us to propose a competitive function of mismatch repair that prevents uracil glycosylase from normal, error-free repair.

RESULTS AND DISCUSSION
======================

The residual A/T mutagenesis observed in MSH2-deficient animals harbors the same overall pattern as the one observed in Ig genes of normal mice, which raises the possibility that it could be generated by pol η, recruited outside the mismatch repair pathway.

We therefore generated *Polh^−/−^Msh2^−/−^* animals and collected a large mutation database from four to seven mice of the single- or double-deficient genotypes. We observed rather large interindividual variations in the mutation frequency, notably between two groups of wild-type mice originating from two separate rooms of the same animal facility ([Table I](#tbl1){ref-type="table"} and [Fig. 1 A](#fig1){ref-type="fig"}). Taking into account the mutation frequency of the pool of mice constituted by the wild-type littermates of the *Polh* heterozygous breeding, the mutation frequency was reduced at least two times in either MSH2- or pol η--MSH2--deficient mice. This reduction is mainly caused by the absence of highly mutated sequences ([Fig. 1 C](#fig1){ref-type="fig"}).

![**Analysis of mutations in rearranged J~H~4 intronic sequences isolated from Peyer\'s patches of controls and pol η--, MSH2- and pol η--MSH2--deficient mice.** (A) Average mutation frequency per individual mouse, expressed relative to total sequences (left) or to mutated sequences (right). The mean values are represented by a horizontal bar. Controls ([@bib2]) represent wild-type littermates of the *Polh* heterozygous breedings, whereas controls ([@bib1]) come from a different module from the same animal facility (the dotted bar is the mean between the two sets of controls). These mean values differ slightly from the ones listed in [Table I](#tbl1){ref-type="table"}, which represent the average mutation frequency of pooled sequences. (B) Pattern of nucleotide substitution in the four different genotypes of mice. Values are expressed as the percentage of total mutations after correction for base composition. (C) Accumulation of mutations in individual J~H~4 intronic sequences. The number of sequences harboring a defined number of mutations relative to the total number of sequences is represented. MSH2-proficient (top) and MSH2-deficient (bottom) backgrounds are shown. All mutations are listed along the J~H~4 intronic sequence in Fig. S2, available at <http://www.jem.org/cgi/content/full/jem.20062131/DC1>.](jem2040017f01){#fig1}

###### 

Somatic mutations in J~H~4 intronic sequences (490 bp) from normal and mutant mice

  ------------------------------------------------------------------------------------------------------------------------
                                              Controls   *pol η^−/−^*   *Msh2^−/−^*   *pol η^−/−^ × Msh2^−/−^*   
  ------------------------------------------- ---------- -------------- ------------- -------------------------- ---------
  Number of sequences                         112        89             193           208                        331

  Total length sequenced (bp)                 54,880     43,610         94,570        101,920                    162,190

  Unmutated sequences (percentage)            25         48             31            50                         60

  Total number of mutations                   624        251            508           242                        310

  Number of deletions and insertions          8          3              6             4                          5

  Mutation frequency per total sequences\     1.15       0.58           0.54          0.24                       0.19
      (per 100 bp)                                                                                               

  Mutation frequency per mutated sequences\   1.54       1.13           0.78          0.48                       0.48
      (per 100 bp)                                                                                               
  ------------------------------------------------------------------------------------------------------------------------

Previous studies have concluded, based on \[^3^H\]thymidine incorporation after different mitogenic stimulations, that MSH2 deficiency did not result in a significant in vitro proliferative defect of splenic B cells, although isotype switching was reduced by two thirds ([@bib7], [@bib27]--[@bib30]). Using carboxyfluorescein diacetate succinimidyl ester (CFSE) labeling during in vitro stimulation of splenic B cells with either LPS or LPS plus IL-4, we observed no difference in proliferation of pol η--deficient B cells compared with controls, and only a marginal effect of MSH2 deficiency, which was, however, not manifest in the double *Pol η*--*Msh2^−/−^* context (Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20062131/DC1>).

pol η--MSH2--deficient mice show the same altered distribution of mutation along the Ig sequence as *Msh2^−/−^* mice do, with a striking clustering at a few G/C hotspot positions: seven hotspots concentrate more than half of the mutations in a sequence of 490 bp ([Fig. 2](#fig2){ref-type="fig"}). Most of them (except one, T[G]{.ul}TT, at position 38 in the J~H~4 intronic sequence, whose targeting is, however, less pronounced in the double-deficient background) correspond to a WGCW sequence, as described previously (W = A or T) ([@bib12]), with either or both internal G and C bases targeted. One major hotspot present in wild-type mice (A[G]{.ul}TT, at position 46) disappears in the absence of MSH2. Similar again to the MSH2-deficient genotype, a strong increase in transitions within G/C mutations is observed in the double-deficient context ([Table II](#tbl2){ref-type="table"}).

![**Hotspot clustering of mutations in MSH2-deficient backgrounds.** The distribution of mutations at G/C bases along the J~H~4 intronic sequence is represented for the four different genetic backgrounds analyzed. The percentage of total mutations represented by the seven major hotspots observed in the *Msh2^−/−^* background (defined arbitrarily as a position mutated in 5% or more of sequences) is calculated for each genotype (marked by asterisks). These seven mutation hotspots occur in the following sequence context (described in their 5′ to 3′ order along the J~H~4 sequence, with the mutated base underlined and the position of the first base of the motif numbered from the J~H~4 intronic border): T[G]{.ul}TT (position 38), A[GC]{.ul}A (position 55), T[GC]{.ul}A (position 60), TG[C]{.ul}T (position 251), and A[G]{.ul}CA (position 362). One hotspot marked with an open triangle (A[G]{.ul}TT, at position 46) is restricted to the MSH2-proficient background.](jem2040017f02){#fig2}

###### 

Pattern of nucleotide changes in J~H~4 intronic sequences of normal and mutant mice

                                                     Within G/C   Within A/T                        
  -------------------------- ----------- ----------- ------------ ------------ ------ ------ ------ ------
  Controls                   49.3:50.7   54.3:45.7   59.1         15.6         25.3   49.5   27.0   23.5
  *pol η^−/−^*               84.4:15.6   53.0:47.0   59.3         11.7         29.0   18.8   24.7   56.5
  *Msh2^−/−^*                89.7:10.3   75.1:24.9   79.6         9.2          11.2   35.6   37.8   26.6
  *pol η^−/−^ × Msh2^−/−^*   99.2:0.8    84.6:15.4   85.3         5.0          9.7    0      75.0   25.0

The main difference between MSH2 and pol η--MSH2-- deficient animals resides in A/T mutations: whereas they represent 10% of mutations in *Msh2^−/−^* mice, they are totally absent in the double knockout mice, with the 4 A/T changes collected in a sample of 310 mutations corresponding to the background of the enzyme used for amplification ([Fig. 1 B](#fig1){ref-type="fig"}). It should be noted that the low mutation frequency linked with the MSH2 genetic defect (in the 2 × 10^−3^ range) obviously requires high fidelity enzymes to collect mutation samples in which the contribution of the amplification step does not exceed a few percent (2--3% in this experiment, with ∼60% of them being As or Ts) ([@bib31]).

It thus appears that pol η is responsible for the residual A/T mutagenesis observed in MSH2-deficient animals by being involved in a mutagenic DNA synthesis that now appears to be driven by the UNG pathway. Taking into account our previous data suggesting that, in pol η--deficient mice, the A/T mutations observed are likely contributed by pol κ recruited in a back-up function, we therefore conclude that, in the normal physiological situation, pol η is the sole polymerase required for A/T mutagenesis at the Ig locus. pol η probably generates some G/C mutations as well, as its mutation spectrum in vitro affects G/C bases in a proportion of ∼20%, with two thirds of them being transitions and one third being transversions ([@bib32]). These numbers fit remarkably well with the 3% of transversion mutations at G/C positions observed in UNG-deficient mice ([@bib6]); indeed, this suggests that 10% of G/C mutations could be generated by pol η via the MSH2 pathway, with one third of them being discernable as transversions in the UNG-deficient context.

Is the small contribution of pol η via the UNG pathway observed in MSH2-deficient animals a physiological process? Although this question might not be easily answered, we would like to argue that the overall mutation pattern of MSH2-deficient animals corresponds to a major alteration of the repair pathways involved, a situation for which, surprisingly, no comprehensive explanation has been brought so far. The seminal work of Rada et al. ([@bib14]) has shown that the mutation pattern of UNG--MSH2--deficient animals reflects the simple footprint of AID deamination and that it is close, in terms of targeting, to the G/C mutation pattern of wild-type animals. It is also quantitatively similar, at least at the V locus, and this striking observation that suggests that both UNG and MSH2 pathways are processing uracils mainly in an error-prone mode. It thus follows that the large decrease in mutation frequency, as well as the increased targeting of specific hotspots observed in the MSH2-deficient background, must be caused by an increased error-free repair of deaminated cytosines by the UNG pathway rather than by modulation of AID targeting by the MSH2--MSH6 complex, as proposed ([@bib12], [@bib33]). The mutation hotspots that emerge could correspond to deamination sites at which the residence time of AID would be increased (possibly through their symmetrical WGCW structure that would result in a stronger binding and/or an inefficient displacement by the sole UNG enzyme), thus preventing repair at those sites. The AGTT hotspot whose occurrence is restricted to the MSH2-proficient background would not provide such strong binding and would be more easily repaired. Error-free repair or ignorance would then be the two major outcomes of AID-induced cytidine deamination in the MSH2-deficient background, resulting in the drop of mutation frequency and the increase in transitions at G/C bases. A small fraction of lesions handled by the UNG pathway would generate abasic sites, leading to transversions when replicated over, or would recruit pol η in an error-prone short patch repair ([Fig. 3](#fig3){ref-type="fig"}).

![**Impact of the MSH2--MSH6 complex on UNG activity during Ig gene hypermutation.** (A) A simplified scheme of hypermutation. UNG would be prevented from performing error-free repair in the presence of MSH2--MSH6 and would generate mainly abasic sites upon uracil recognition. These DNA lesions would be copied by a set of translesional DNA polymerases (among which are Rev1, Rev3, and possibly pol θ \[references [@bib36]--[@bib40]\], albeit the contribution of this latter enzyme was recently shown to be less likely \[reference [@bib41]\]), acting in S phase in their function of lesion bypass. MSH2--MSH6 would recruit pol η in an error-prone short patch synthesis of the uracil-containing strand, most likely in G1 (reference [@bib42]). (B) Outline of a possible altered behavior of UNG in the absence of MSH2 and of its consequences on hypermutation in *Msh2^−/−^* mice. (left) Increase of error-free repair (resulting in a reduced mutation frequency). (middle) Recruitment of pol η for an error-prone short patch repair (residual A/T mutagenesis). (right) Inefficient displacement of AID (increase in transitions at G/C), in particular at WGCW sites (increased focusing of mutations at specific hotspot positions).](jem2040017f03){#fig3}

Collectively, these data emphasize the very dissymmetrical role that the UNG and MSH2 pathways play in the hypermutation process. UNG deficiency affects mainly the nature of G/C mutations, which are biased almost exclusively toward transitions, while having only a moderate impact on the A/T mutagenesis driven by MSH2 ([@bib6], [@bib34]) and none on the mutation frequency. In contrast, the absence of mismatch repair leads to a stronger modification of the Ig gene mutation pattern, affecting not only mutations at A/T bases, as would be expected from a function symmetrical to the one of UNG, but also the overall mutation frequency and, within G/C mutations, the proportion of transitions as well as their distribution along the Ig sequence. Overall, this suggests that, although the function of MSH2--MSH6 is relatively independent from UNG, the mismatch repair complex strongly impinges on the role of UNG during hypermutation by preventing it to perform its natural error-free repair function.

The behavior of UNG in the mismatch repair--deficient context strikingly mirrors the effect of the deliberate overexpression of another uracil glycosylase, SMUG1, in a UNG--MSH2--deficient background, which results in a major error-free repair accompanied by a smaller error-prone activity generating A/T mutations and G/C transversions ([@bib35]).

In conclusion, the exclusive formation of A/T mutations by pol η allows the formulation of a simplified scheme for the role of translesional polymerases in hypermutation ([Fig. 3](#fig3){ref-type="fig"}). pol η would be recruited by the MSH2--MSH6 complex outside of the S phase to permit U/G mismatch recognition, and would mostly generate A/T but also a small amount of G/C mutations in an error-prone short patch repair process that appears thus far restricted to B cells. In contrast, most G/C mutations would be generated by several translesion DNA polymerases ([@bib33]--[@bib38]), whose exact number remains to be established, acting during replication in their function of lesion bypass by copying abasic sites generated by UNG, which is diverted by MSH2 from its error-free function. In such a model of hypermutation, and in contrast to their physiological repair function, UNG would trigger a translesional process at the replication fork, whereas MSH2--MSH6 would induce a base excision repair outside replication, most probably in the G1 phase of the cell cycle. The involvement of pol η in an error-prone process, whether driven by MSH2 during physiological hypermutation or by uracil glycosylases in specific experimental settings, thus appears to be a B cell--specific event whose biochemical basis remains to be established.

MATERIALS AND METHODS
=====================

Generation of gene-targeted mice.
---------------------------------

*Polh-Msh2* double knockout mice were obtained by breeding the previously described *Polh^−/−^* mouse strain ([@bib19]) with *Msh2^−/−^* animals provided by Hein te Riele (The Netherlands Cancer Institute, Amsterdam, Netherlands). Both genes are located distantly enough on chromosome 17 to allow the efficient recovery of their combined inactivation by mouse breeding. All MSH2-deficient animals selected for analysis were devoid of overt tumors. Generation of gene-targeted mice and breeding was performed by the Service d\'Expérimentation Animale et de Transgénèse. Experiments were performed according to the Institut national de la santé et de la recherche médicale guidelines for laboratory animals and were approved by the Scientific Committee of the Necker Animal Facility.

B cell proliferation assays.
----------------------------

Splenic B cells were isolated from individual 2--3-mo-old mice by negative selection using the Mouse B Cell Isolation Kit (Miltenyi Biotec). Purified B cells were labeled with 5 μM CFSE, according to the manufacturer\'s instructions (Vybrant CFDA SE Cell Tracer Kit; Invitrogen), before stimulation with either 20 μg/ml *Escherichia coli* LPS (serotype 055:B5; Sigma-Aldrich) or 20 μg LPS plus 10 ng/ml IL-4 (Preprotech). CFSE-labeled cells were analyzed after 3 d of stimulation, with forward scatter gating on live cells.

Sequence analysis.
------------------

B220^+^PNA^high^ B cells were isolated from Peyer\'s patches of 4--6-mo-old animals as previously described ([@bib8]). The J~H~4 intron flanking rearranged V~H~ sequences was amplified using a mixture of five V~H~ primers designed to amplify most of the mouse V~H~ families and a downstream primer allowing the determination of 490 bp of noncoding sequences, as reported previously ([@bib19]).

Online supplemental material.
-----------------------------

Fig. S1 shows in vitro proliferation of splenic B cells from wild-type, *Polh^−/−^*, *Msh2^−/−^*, and *Msh2^−/−^Polh^−/−^* mice. Fig. S2 depicts the distribution of mutations along the J~H~4 intronic sequence in Peyer\'s patch PNA^high^ B cells from wild-type, *Polh^−/−^*, *Msh2^−/−^*, and *Msh2^−/−^Polh^−/−^* mice. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20062131/DC1>.
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